COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 358-367

  Litchfield, Lacey M ^a   Appana, Savitri N ^b   Datta, Susmita ^b   Klinge, Carolyn M ^a  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Antiestrogens; Drug resistance; Nuclear receptors; Tamoxifen; Transcription factors

Indexed keywords

4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; AFIMOXIFENE; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; CYTOKINE; DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA BINDING; GENE EXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HORMONE RESISTANCE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; INHIBITION KINETICS; PHENOTYPE; PRIORITY JOURNAL; TRANSACTIVATION;

4-HYDROXYTAMOXIFEN; 4-OHT; A20/TNFAIP3; ANTIESTROGENS; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR II; COUP-TFII; DRUG RESISTANCE; ERΑ; ESTROGEN RECEPTOR; ICAM1; IL6; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6 (IL6); NFΚB/NFKAPPA B; NUCLEAR FACTOR ΚB; NUCLEAR RECEPTORS; QPCR; QUANTITATIVE REAL-TIME PCR; RE; RESPONSE ELEMENT; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SERD; SERM; TAM; TAMOXIFEN; TNFΑ; TNFΑ-INDUCED PROTEIN 3; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR;

BREAST NEOPLASMS; COUP TRANSCRIPTION FACTOR II; DNA, NEOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; IMIDAZOLES; MCF-7 CELLS; NF-KAPPA B; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN SUBUNITS; QUINOXALINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR RELA;

EID: 84887564189     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.10.010     Document Type: Article

References (58)

1. Bren G.D., Solan N.J., Miyoshi H., Pennington K.N., Pobst L.J., Paya C.V. Transcription of the RelB gene is regulated by NF-kappaB. Oncogene 2001, 20:7722-7733.
2. Brunner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C., Lippman J., Frandsen T., Spang-Thomsen M., Fuqua S.A., Clarke R. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997, 57:3486-3493.
3. Burke J.R., Pattoli M.A., Gregor K.R., Brassil P.J., MacMaster J.F., McIntyre K.W., Yang X., Iotzova V.S., Clarke W., Strnad J., Qiu Y., Zusi F.C. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J. Biol. Chem. 2003, 278:1450-1456.
4. Chew J., Biswas S., Shreeram S., Humaidi M., Wong E.T., Dhillion M.K., Teo H., Hazra A., Fang C.C., Lopez-Collazo E., Bulavin D.V., Tergaonkar V. WIP1 phosphatase is a negative regulator of NF-kappaB signalling. Nat. Cell Biol. 2009, 11:659-666.
5. Cogswell P.C., Guttridge D.C., Funkhouser W.K., Baldwin A.S. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000, 19:1123-1131.
6. Dell H., Hadzopoulou-Cladaras M. CREB-binding protein is a transcriptional coactivator for hepatocyte nuclear factor-4 and enhances apolipoprotein gene expression. J. Biol. Chem. 1999, 274:9013-9021.
7. Early Breast Cancer Trialists' Collaborative, G., 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, vol. 365, pp. 1687-1717.
8. Edderkaoui M., Odinokova I., Ohno I., Gukovsky I., Go V.L., Pandol S.J., Gukovskaya A.S. Ellagic acid induces apoptosis through inhibition of nuclear factor kappa B in pancreatic cancer cells. World J. Gastroenterol. 2008, 14:3672-3680.
9. Gao Z., Chiao P., Zhang X., Zhang X., Lazar M.A., Seto E., Young H.A., Ye J. Coactivators and corepressors of NF-kappaB in IkappaB alpha gene promoter. J. Biol. Chem. 2005, 280:21091-21098.
10. Gu Z., Lee R.Y., Skaar T.C., Bouker K.B., Welch J.N., Lu J., Liu A., Zhu Y., Davis N., Leonessa F., Brunner N., Wang Y., Clarke R. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-kappaB, and cyclic AMP response element binding with acquired resistance to faslodex (ICI 182,780). Cancer Res. 2002, 62:3428-3437.
11. Hannink M., Temin H.M. Structure and autoregulation of the c-rel promoter. Oncogene 1990, 5:1843-1850.
12. Huber M.A., Azoitei N., Baumann B., Grunert S., Sommer A., Pehamberger H., Kraut N., Beug H., Wirth T. NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J. Clin. Invest. 2004, 114:569-581.
13. Jobin C., Bradham C.A., Russo M.P., Juma B., Narula A.S., Brenner D.A., Sartor R.B. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J. Immunol. 1999, 163:3474-3483.
14. Jordan V.C. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res. 2009, 69:1243-1254.
15. Kim Y.-M., Cao D., Reed W., Wu W., Jaspers I., Tal T., Bromberg P.A., Samet J.M. Zn2+ -induced NF-κB-dependent transcriptional activity involves site-specific p65/RelA phosphorylation. Cell. Signal. 2007, 19:538-546.
16. Knupfer H., Preiss R. Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res. Treat. 2007, 102:129-135.
17. Koh S.S., Chen D., Lee Y.H., Stallcup M.R. Synergistic enhancement of nuclear receptor function by p160 coactivators and two coactivators with protein methyltransferase activities. J. Biol. Chem. 2001, 276:1089-1098.
18. Korkaya H., Kim G.I., Davis A., Malik F., Henry N.L., Ithimakin S., Quraishi A.A., Tawakkol N., D'Angelo R., Paulson A.K., Chung S., Luther T., Paholak H.J., Liu S., Hassan K.A., Zen Q., Clouthier S.G., Wicha M.S. Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol. Cell. 2012, 47:570-584.
19. Krikos A., Laherty C.D., Dixit V.M. Transcriptional activation of the tumor necrosis factor alpha-inducible zinc finger protein, A20, is mediated by kappa B elements. J. Biol. Chem. 1992, 267:17971-17976.
20. Lanz R.B., McKenna N.J., Onate S.A., Albrecht U., Wong J., Tsai S.Y., Tsai M.J., O'Malley B.W. A steroid receptor coactivator, SRA, functions as an RNA and is present in an SRC-1 complex. Cell 1999, 97:17-27.
21. Lerebours F., Vacher S., Andrieu C., Espie M., Marty M., Lidereau R., Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008, 8:41.
22. Litchfield L.M., Klinge C.M. Multiple roles of COUP-TFII in cancer initiation and progression. J. Mol. Endocrinol. 2012, 49:R149-R156.
23. Litchfield L.M., Riggs K.A., Hockenberry A.M., Oliver L.D., Barnhart K.G., Cai J., Pierce W.M., Ivanova M.M., Bates P.J., Appana S.N., Datta S., Kulesza P., McBryan J., Young L.S., Klinge C.M. Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor beta transcription in breast cancer cells. PLoS One 2012, 7:e38278.
24. Lombardi L., Ciana P., Cappellini C., Trecca D., Guerrini L., Migliazza A., Maiolo A.T., Neri A. Structural and functional characterization of the promoter regions of the NFKB2 gene. Nucl. Acids Res. 1995, 23:2328-2336.
25. Mandlekar S., Kong A.N. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001, 6:469-477.
26. More E., Fellner T., Doppelmayr H., Hauser-Kronberger C., Dandachi N., Obrist P., Sandhofer F., Paulweber B. Activation of the MAP kinase pathway induces chicken ovalbumin upstream promoter-transcription factor II (COUP-TFII) expression in human breast cancer cell lines. J. Endocrinol. 2003, 176:83-94.
27. Muscat G.E., Eriksson N.A., Byth K., Loi S., Graham D., Jindal S., Davis M.J., Clyne C., Funder J.W., Simpson E.R., Ragan M.A., Kuczek E., Fuller P.J., Tilley W.D., Leedman P.J., Clarke C.L. Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer. Mol. Endocrinol. 2013, 27:350-365.
28. Nakshatri H., Bhat-Nakshatri P., Martin D.A., Goulet R.J., Sledge G.W. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 1997, 17:3629-3639.
29. Nehra R., Riggins R.B., Shajahan A.N., Zwart A., Crawford A.C., Clarke R. BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J. 2010, 24:2040-2055.
30. Opipari A.W., Hu H.M., Yabkowitz R., Dixit V.M. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J. Biol. Chem. 1992, 267:12424-12427.
31. Panguluri S.K., Bhatnagar S., Kumar A., McCarthy J.J., Srivastava A.K., Cooper N.G., Lundy R.F. Genomic profiling of messenger RNAs and microRNAs reveals potential mechanisms of TWEAK-induced skeletal muscle wasting in mice. PLoS One 2010, 5:e8760.
32. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell. Biol. 2007, 8:49-62.
33. Prasad S., Ravindran J., Aggarwal B.B. NF-kappaB and cancer: how intimate is this relationship. Mol. Cell. Biochem. 2010, 336:25-37.
34. Pratt M.A., Bishop T.E., White D., Yasvinski G., Menard M., Niu M.Y., Clarke R. Estrogen withdrawal-induced NF-kappaB activity and bcl-3 expression in breast cancer cells: roles in growth and hormone independence. Mol. Cell. Biol. 2003, 23:6887-6900.
35. Qiu Y., Krishnan V., Zeng Z., Gilbert D.J., Copeland N.G., Gibson L., Yang-Feng T., Jenkins N.A., Tsai M.J., Tsai S.Y. Isolation, characterization, and chromosomal localization of mouse and human COUP-TF I and II genes. Genomics 1995, 29:240-246.
36. Riggins R.B., Zwart A., Nehra R., Clarke R. The nuclear factor kappa B inhibitor parthenolide restores ICI 182,780 (Faslodex; fulvestrant)-induced apoptosis in antiestrogen-resistant breast cancer cells. Mol. Cancer Ther. 2005, 4:33-41.
37. Riggs K.A., Wickramasinghe N.S., Cochrum R.K., Watts M.B., Klinge C.M. Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res. 2006, 66:10188-10198.
38. Ring A., Dowsett M. Mechanisms of tamoxifen resistance. Endocr. Relat. Cancer 2004, 11:643-658.
39. Rosette C., Roth R.B., Oeth P., Braun A., Kammerer S., Ekblom J., Denissenko M.F. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005, 26:943-950.
40. Salami S., Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines. Clin. Biochem. 2003, 36:247-253.
41. Sansone P., Storci G., Tavolari S., Guarnieri T., Giovannini C., Taffurelli M., Ceccarelli C., Santini D., Paterini P., Marcu K.B., Chieco P., Bonafe M. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 2007, 117:3988-4002.
42. Silverman M.D., Zamora D.O., Pan Y., Texeira P.V., Planck S.R., Rosenbaum J.T. Cell adhesion molecule expression in cultured human iris endothelial cells. Invest. Ophthalmol. Visual Sci. 2001, 42:2861-2866.
43. Singh S., Aggarwal B.B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J. Biol. Chem. 1995, 270:24995-25000.
44. Song C.H., Lee H.J., Park E., Lee K. The chicken ovalbumin upstream promoter-transcription factor II negatively regulates the transactivation of androgen receptor in prostate cancer cells. PLoS One 2012, 7:e49026.
45. Soria G., Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008, 267:271-285.
46. Sovak M.A., Bellas R.E., Kim D.W., Zanieski G.J., Rogers A.E., Traish A.M., Sonenshein G.E. Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J. Clin. Invest. 1997, 100:2952-2960.
47. Symmans, W.F., Hatzis, C., Sotiriou, C., Andre, F., Peintinger, F., Regitnig, P., Daxenbichler, G., Desmedt, C., Domont, J., Marth, C., Delaloge, S., Bauernhofer, T., Valero, V., Booser, D.J., Hortobagyi, G.N., Pusztai, L., 2010 Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. J. Clin. Oncol. (JCO.2010.28.4273).
48. Ten R.M., Paya C.V., Israel N., Le Bail O., Mattei M.G., Virelizier J.L., Kourilsky P., Israel A. The characterization of the promoter of the gene encoding the p50 subunit of NF-kappa B indicates that it participates in its own regulation. EMBO J. 1992, 11:195-203.
49. Vendrell J.A., Ghayad S., Ben-Larbi S., Dumontet C., Mechti N., Cohen P.A. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells. Oncogene 2007, 26:4656-4667.
50. Wang D., Baldwin A.S. Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529. J. Biol. Chem. 1998, 273:29411-29416.
51. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999, 140:5828-5840.
52. Yde C.W., Emdal K.B., Guerra B., Lykkesfeldt A.E. NFkappaB signaling is important for growth of antiestrogen resistant breast cancer cells. Breast Cancer Res. Treat. 2012, 135:67-78.
53. Yun J.J., Tsao M.S., Der S.D. Differential utilization of NF-kappaB RELA and RELB in response to extracellular vs. intracellular polyIC stimulation in HT1080 cells. BMC Immunol. 2011, 12:15.
54. Zhang X., Wang J.M., Gong W.H., Mukaida N., Young H.A. Differential regulation of chemokine gene expression by 15-deoxy-delta 12,14 prostaglandin J2. J. Immunol. 2001, 166:7104-7111.
55. Zhao L., Lee J.Y., Hwang D.H. The phosphatidylinositol 3-kinase/Akt pathway negatively regulates Nod2-mediated NF-kappaB pathway. Biochem. Pharmacol. 2008, 75:1515-1525.
56. Zhou Y., Eppenberger-Castori S., Eppenberger U., Benz C.C. The NFkappaB pathway and endocrine-resistant breast cancer. Endocrine-Relat. Cancer 2005, 12(Suppl 1). S37-46.
57. Zhou Y., Eppenberger-Castori S., Marx C., Yau C., Scott G.K., Eppenberger U., Benz C.C. Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell. Biol. 2005, 37:1130-1144.
58. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., Eppenberger U., Eppenberger-Castori S., Benz C.C. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59.